SG10202101500WA - PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS - Google Patents

PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS

Info

Publication number
SG10202101500WA
SG10202101500WA SG10202101500WA SG10202101500WA SG10202101500WA SG 10202101500W A SG10202101500W A SG 10202101500WA SG 10202101500W A SG10202101500W A SG 10202101500WA SG 10202101500W A SG10202101500W A SG 10202101500WA SG 10202101500W A SG10202101500W A SG 10202101500WA
Authority
SG
Singapore
Prior art keywords
treatment
bone disorders
pparγ agonist
pparγ
agonist
Prior art date
Application number
SG10202101500WA
Other languages
English (en)
Inventor
Dennis Lanfear
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of SG10202101500WA publication Critical patent/SG10202101500WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
SG10202101500WA 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS SG10202101500WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18

Publications (1)

Publication Number Publication Date
SG10202101500WA true SG10202101500WA (en) 2021-03-30

Family

ID=61197122

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202101500WA SG10202101500WA (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS
SG11201901328VA SG11201901328VA (en) 2016-08-18 2017-08-18 Ppar? agonist for treatment of bone disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201901328VA SG11201901328VA (en) 2016-08-18 2017-08-18 Ppar? agonist for treatment of bone disorders

Country Status (11)

Country Link
US (1) US20190167660A1 (https=)
EP (1) EP3500269A4 (https=)
JP (2) JP2019524889A (https=)
KR (1) KR20190065252A (https=)
CN (1) CN109843292A (https=)
AU (1) AU2017313842A1 (https=)
BR (1) BR112019003133A2 (https=)
CA (1) CA3033971A1 (https=)
EA (1) EA201990513A1 (https=)
SG (2) SG10202101500WA (https=)
WO (1) WO2018035449A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2785317T3 (es) * 2014-10-10 2020-10-06 Liminal Biosciences Ltd Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis

Also Published As

Publication number Publication date
KR20190065252A (ko) 2019-06-11
EP3500269A4 (en) 2020-04-15
SG11201901328VA (en) 2019-03-28
EA201990513A1 (ru) 2019-08-30
US20190167660A1 (en) 2019-06-06
WO2018035449A1 (en) 2018-02-22
BR112019003133A2 (pt) 2019-05-21
AU2017313842A1 (en) 2019-03-07
JP2022116294A (ja) 2022-08-09
CA3033971A1 (en) 2018-02-22
JP2019524889A (ja) 2019-09-05
CN109843292A (zh) 2019-06-04
EP3500269A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL257978A (en) Use of pasteurized acrementia to treat metabolic diseases
IL253945B (en) kdm1a inhibitors to treat the disease
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
IL247453A0 (en) Amide compounds for the treatment of complement-mediated disorders
PL3143025T3 (pl) Związki do leczenia rdzeniowego zaniku mięśni
IL258032B (en) Compounds and preparations for the treatment of ocular disorders
IL258593A (en) Compounds for the treatment of subculture disorders
IL274223A (en) Methods for treating acid-base disorders
IL270576B (en) Hetero-aromatic-aniline compounds for the treatment of skin disorders
IL269604A (en) Pentides for the treatment of autoimmune diseases
GB201612043D0 (en) Composition for treatment of disorders
SG10202101501PA (en) PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL257935A (en) Treatment of bone growth disorders
SG10202101500WA (en) PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS
IL274747A (en) FXR agonists for the treatment of liver diseases
IL266243A (en) Use of senicapoc for the treatment of neuropathic pain
EP3200795A4 (en) Use of agents for treating fat-related disorders
GB201604359D0 (en) Treatment of tissue disorders
HK40010577A (en) Pparϒ agonist for treatment of bone disorders
PL3638223T3 (pl) Bromheksyna w leczeniu bólu